16 Dec Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]South San Francisco, CA – December 16, 2020 /PRNewswire/ -- Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been...